Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Payables (2022 - 2025)

Historic Payables for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $5.8 million.

  • Day One Biopharmaceuticals' Payables rose 9151.47% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year increase of 9151.47%. This contributed to the annual value of $3.3 million for FY2024, which is 2663.04% up from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Payables stood at $5.8 million, which was up 9151.47% from $5.1 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Payables ranged from a high of $16.0 million in Q4 2022 and a low of $439000.0 during Q2 2022
  • In the last 4 years, Day One Biopharmaceuticals' Payables had a median value of $4.0 million in 2022 and averaged $4.5 million.
  • Over the last 5 years, Day One Biopharmaceuticals' Payables had its largest YoY gain of 93986.33% in 2023, and its largest YoY loss of 8384.95% in 2023.
  • Over the past 4 years, Day One Biopharmaceuticals' Payables (Quarter) stood at $16.0 million in 2022, then crashed by 83.85% to $2.6 million in 2023, then rose by 26.63% to $3.3 million in 2024, then surged by 77.13% to $5.8 million in 2025.
  • Its last three reported values are $5.8 million in Q3 2025, $5.1 million for Q2 2025, and $2.5 million during Q1 2025.